Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter Reinisch

Showing results (321-330 of 352) with videos related to

Pageof 36
Sort By:
Journal of Crohn'S & Colitis|May 10, 2015
The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS]Simon P L Travis, Dan Schnell, Brian G Feagan, et al.
Inflammatory Bowel Diseases|August 29, 2009
Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitisDaniel C Baumgart, Stephan R Targan, Axel U Dignass, et al.
Inflammatory Bowel Diseases|January 2, 2021
Inflammatory Bowel Disease and Risk of Major Bleeding During Anticoagulation for Venous ThromboembolismSusanna Scharrer, Christian Primas, Sabine Eichinger, et al.
Gut|May 19, 2012
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trialWolfgang Hueber, Bruce E Sands, Steve Lewitzky, et al.
Gastroenterology|July 30, 2013
Reliability and initial validation of the ulcerative colitis endoscopic index of severitySimon P L Travis, Dan Schnell, Piotr Krzeski, et al.
Gut|October 7, 2017
Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA studyWilliam J Sandborn, Scott D Lee, Dino Tarabar, et al.
Gut|October 15, 2011
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)Simon P L Travis, Dan Schnell, Piotr Krzeski, et al.
Gastroenterology|February 8, 2022
Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 StudyWilliam J Sandborn, Geert R D'Haens, Walter Reinisch, et al.
United European Gastroenterology Journal|October 5, 2024
Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: A systematic review and future perspectiveTommaso Lorenzo Parigi, Virginia Solitano, Alessandro Armuzzi, et al.
Journal of Crohn'S & Colitis|December 3, 2010
Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infectionShomron Ben-Horin, Maya Margalit, Peter Bossuyt, et al.
Pageof 36

Showing results (321-330 of 352) with videos related to

Sort By:
Pageof 36
Journal of Crohn'S & Colitis|May 10, 2015
The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS]Simon P L Travis, Dan Schnell, Brian G Feagan, et al.
Inflammatory Bowel Diseases|August 29, 2009
Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitisDaniel C Baumgart, Stephan R Targan, Axel U Dignass, et al.
Inflammatory Bowel Diseases|January 2, 2021
Inflammatory Bowel Disease and Risk of Major Bleeding During Anticoagulation for Venous ThromboembolismSusanna Scharrer, Christian Primas, Sabine Eichinger, et al.
Gut|May 19, 2012
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trialWolfgang Hueber, Bruce E Sands, Steve Lewitzky, et al.
Gastroenterology|July 30, 2013
Reliability and initial validation of the ulcerative colitis endoscopic index of severitySimon P L Travis, Dan Schnell, Piotr Krzeski, et al.
Gut|October 7, 2017
Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA studyWilliam J Sandborn, Scott D Lee, Dino Tarabar, et al.
Gut|October 15, 2011
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)Simon P L Travis, Dan Schnell, Piotr Krzeski, et al.
Gastroenterology|February 8, 2022
Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 StudyWilliam J Sandborn, Geert R D'Haens, Walter Reinisch, et al.
United European Gastroenterology Journal|October 5, 2024
Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: A systematic review and future perspectiveTommaso Lorenzo Parigi, Virginia Solitano, Alessandro Armuzzi, et al.
Journal of Crohn'S & Colitis|December 3, 2010
Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infectionShomron Ben-Horin, Maya Margalit, Peter Bossuyt, et al.
Pageof 36